Cash figures as of 2026-08-13. Database snapshot: 2026-09-21.
Price history
Loading SLXN daily closes…
Loading price history…
Pipeline assets
SIL204
Phase 2/3 · ActiveModality: siRNA
Target KRAS
Indications
Locally advanced pancreatic cancer (KRAS-driven cancers)(Phase 2/3)
Status note Lead product candidate; second-generation siRNA targeting KRAS. Phase 2/3 human clinical trial initiated in July 2026.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.